SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Yoshinobu Onuma; Patrick W. Serruys; the SPIRIT II Investigators; Thorax Center

doi:10.1016/s0735-1097(10)61136-9

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Journal of the American College of Cardiology 55(10): A121.E1135-A121.E1135

Article 2010 English

Related publications

Article2011

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS: 5-YEAR RESULTS

Yoshinobu Onuma, Patrick W. Serruys

Journal of the American College of Cardiology

Article2009

Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions

Bimmer E. Claessen, Marcel A.M. Beijk, Victor Legrand, Witold Rużyłło, Antonio Manari, Olivier Varenne, Maarten J. Suttorp, Jan G.P. Tijssen, Karine Miquel‐Hébert, Susan Veldhof, José P.S. Henriques, Patrick W. Serruys, Jan J. Piek

Circulation Cardiovascular Interventions

Article2010

Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT II trial

Scot Garg, Patrick W. Serruys, Karine Miquel‐Hébert

Catheterization and Cardiovascular Interventions

Article2009

3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions

Scot Garg, Patrick W. Serruys, Yoshinobu Onuma, Cécile Dorange, Susan Veldhof, Karine Miquel‐Hébert, Krishnankutty Sudhir, Jean Boland, Kurt Huber, Eulogio Garcı́a, Jan A.M. te Riele

КАРДИОЛОГИЯ УЗБЕКИСТАНА

Article2010

Five‐year long‐term clinical follow‐up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT FIRST trial

Marcus Wiemer, Patrick W. Serruys, Karine Miquel‐Hébert, Franz‐Josef Neumann, Jan J. Piek, Eberhard Grube, Jürgen Haase, Leif Thuesen, Christian W. Hamm

Catheterization and Cardiovascular Interventions

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

Abstract

Discussion(0)

Related publications

SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS: 5-YEAR RESULTS

Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions

Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT II trial

3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions

Five‐year long‐term clinical follow‐up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT FIRST trial